Phase 3 Dravet Stoke is advancing zorevunersen in a pivotal Phase 3 trial for Dravet syndrome, signaling a potential near-term commercial path and a need for partnership opportunities in CNS disease management and rare genetic conditions.

Haploinsufficiency Focus The company targets diseases caused by haploinsufficiency (loss of ~50% protein), suggesting collaboration opportunities with rare disease programs that could expand into neuro and ocular indications using the TANGO ASO platform.

Donor/Partner Potential Active investor and industry engagement evidenced by frequent conference participation and CEO leadership changes; a favorable environment for BD outreach to strategic partners, potential co-development or licensing deals around antisense therapies.

CNS and Eye Triage Primary focus on central nervous system and eye diseases implies targeted sales plays with specialty clinics, patient advocacy groups, and payer discussions for premium therapies addressing unmet needs in haploinsufficiency-driven disorders.

Clinical Momentum Recent news coverage and ongoing communications about TANGO-based ASOs reinforce market interest and potential fastest routes to market, presenting timely occasions for early-access programs, collaboration, and visibility with key stakeholders.